Search results
Results from the WOW.Com Content Network
The efficacy of solifenacin to treat neurogenic detrusor overactivity (NDO) was established in two clinical trials with a total of 95 pediatric NDO participants, ages two to 17 years old. [2] The studies were designed to measure (as a primary efficacy endpoint) the maximum amount of urine the bladder could hold after 24 weeks of treatment. [2]
The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, commonly called the Beers List, [1] are guidelines published by the American Geriatrics Society (AGS) for healthcare professionals to help improve the safety of prescribing medications for adults 65 years and older in all except palliative settings.
The CDC recommends three flu vaccines for people 65 and older: the Fluzone High-Dose inactivated flu ... Research shows that the vaccine is most effective in the first year and wanes over 10 years.
[13] [4] [2] [1] It works equally well to antimuscarinic medication such as solifenacin or tolterodine. [6] [3] In the United Kingdom it is less preferred to these agents. [7] Mirabegron is also indicated to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and ...
Each year, RSV infections cause about 177,000 hospitalizations and 14,000 deaths in adults aged 65 and older, per CDC data. It also leads to about 58,000 hospitalizations and 500 deaths in ...
These abbreviations can be verified in reference works, both recent [1] and older. [2] [3] [4] Some of those works (such as Wyeth 1901 [4]) are so comprehensive that their entire content cannot be reproduced here. This list includes all that are frequently encountered in today's health care in English-speaking regions.
Over time, a deficiency of B12 can cause problems with balance, confusion, depression, poor memory and possibly dementia, and it can even cause permanent damage to the nervous system, Somers says.
If there is no guidance then pick the mid point between the dose range extremes. The DDD of a drug is reviewed after three years. Ad hoc requests for change may be made but are discouraged and generally not permitted unless the main indication for the drug has changed or the average dose used has changed by more than 50%. [3]